Glikopeptitlerin Etki Spektrumu ve Kullanım Alanları

Rybak M. J. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clinical infectious diseases. an official publication of the Infectious Diseases Society of America;2006;42(1): S35–S39. doi:10.1086/491712

Moise, P. A., Forrest, A., Bhavnani, S. M, et al. Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. American journal of health-system pharmacy. 2000;57(2): 4–9. doi:10.1093/ajhp/57.suppl_2.S4

Moise-Broder, P. A., Forrest, A., Birmingham, M. C, et al. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clinical pharmacokinetics. 2004;43(13): 925–942. doi:10.2165/00003088-200443130-00005

Rybak, M., Lomaestro, B., Rotschafer, J. C, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. American journal of health-system pharmacy. 2009;66(1): 82–98. doi:10.2146/ajhp080434

Moellering R. C., Jr. Pharmacokinetics of vancomycin. The Journal of antimicrobial chemotherapy. 1984;14 Suppl D: 43–52. doi:10.1093/jac/14.suppl_d.43

Liu, C., Bayer, A., Cosgrove, S. E, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clinical infectious diseases. an official publication of the Infectious Diseases Society of America;2010;52(3): e18–e55. doi:10.1093/cid/ciq146

Stevens, D. L., Bisno, A. L., Chambers, H. F, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clinical infectious diseases. an official publication of the Infectious Diseases Society of America;2005;41(10): 1373–1406. doi:10.1086/497143

Tunkel, A. R., Hartman, B. J., Kaplan, S. L, et al. Practice guidelines for the management of bacterial meningitis. Clinical infectious diseases. an official publication of the Infectious Diseases Society of America;2004;39(9): 1267–1284. doi:10.1086/425368

Aguilar, J., Urday-Cornejo, V., Donabedian, S, et al. Staphylococcus aureus meningitis: case series and literature review. Medicine. 2010;89(2): 117–125. doi:10.1097/MD.0b013e3181d5453d

Rubinstein, E., Cammarata, S., Oliphant, T, et al. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clinical infectious diseases. an official publication of the Infectious Diseases Society of America;2001;32(3): 402–412. doi:10.1086/318486

Wunderink, R. G., Cammarata, S. K., Oliphant, T. H, et al. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clinical therapeutics. 2003;25(3): 980–992. doi:10.1016/s0149-2918(03)80118-2

Jung, Y. J., Koh, Y., Hong, S. B, et al. Effect of vancomycin plus rifampicin in the treatment of nosocomial methicillin-resistant Staphylococcus aureus pneumonia. Critical care medicine. 2010;38(1): 175–180. doi:10.1097/ccm.0b013e3181b9ecea

Dombrowski, J. C., & Winston, L. G. Clinical failures of appropriately-treated methicillin-resistant Staphylococcus aureus infections. The Journal of infection. 2008;57(2): 110–115. doi:10.1016/j.jinf.2008.04.003

Daver, N. G., Shelburne, S. A., Atmar, R. L, et al. Oral step-down therapy is comparable to intravenous therapy for Staphylococcus aureus osteomyelitis. The Journal of infection. 2007;54(6): 539–544. doi:10.1016/j.jinf.2006.11.011

Bartlett J. G. Clinical practice. Antibiotic-associated diarrhea. The New England journal of medicine. 2002;346(5): 334–339. doi:10.1056/NEJMcp011603

Zar, F. A., Bakkanagari, S. R., Moorthi, K. M, et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clinical infectious diseases. an official publication of the Infectious Diseases Society of America;2007;45(3): 302–307. doi:10.1086/519265

Lipsky, B. A., Baker, C. A., McDonald, L. L, et al. Improving the appropriateness of vancomycin use by sequential interventions. American journal of infection control. 1999;27(2): 84–91. doi:10.1016/s0196-6553(99)70086-6

Cohen, S. H., Gerding, D. N., Johnson, S, et al. Society for Healthcare Epidemiology of America, & Infectious Diseases Society of America. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infection control and hospital epidemiology. 2010;31(5): 431–455. doi:10.1086/651706

Freifeld, A. G., Bow, E. J., Sepkowitz, K. A, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clinical infectious diseases. an official publication of the Infectious Diseases Society of America;2011;52(4): e56–e93. doi:10.1093/cid/cir073

Wilson A. P. (2000). Clinical pharmacokinetics of teicoplanin. Clinical pharmacokinetics, 39(3), 167–183. doi:10.2165/00003088-200039030-00001

Garazzino, S., Aprato, A., Baietto, L, et al. Glycopeptide bone penetration in patients with septic pseudoarthrosis of the tibia. Clinical pharmacokinetics. 2008;47(12): 793–805. doi:10.2165/0003088-200847120-00004

Mimoz, O., Rolland, D., Adoun, M, et al. Steady-state trough serum and epithelial lining fluid concentrations of teicoplanin 12 mg/kg per day in patients with ventilator-associated pneumonia. Intensive care medicine. 2006;32(5): 775–779. doi:10.1007/s00134-006-0136-3

Wilson, A. P., Grüneberg, R. N., & Neu, H. A critical review of the dosage of teicoplanin in Europe and the USA. International journal of antimicrobial agents. 1994;4(1): 1–30. doi:10.1016/0924-8579(94)90049-3

Svetitsky, S., Leibovici, L., & Paul, M. Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis. Antimicrobial agents and chemotherapy. 2009;53(10): 4069–4079. doi:10.1128/AAC.00341-09

Yoon, Y. K., Park, D. W., Sohn, J. W, et al. Multicenter prospective observational study of the comparative efficacy and safety of vancomycin versus teicoplanin in patients with health care-associated methicillin-resistant Staphylococcus aureus bacteremia. Antimicrobial agents and chemotherapy. 2014;58(1): 317–324. doi:10.1128/AAC.00520-13

Tornero, E., García-Ramiro, S., Martínez-Pastor, J. C, et al. Prophylaxis with teicoplanin and cefuroxime reduces the rate of prosthetic joint infection after primary arthroplasty. Antimicrobial agents and chemotherapy. 2015;59(2): 831–837. doi:10.1128/AAC.03949-14

Van Bambeke F. (2004). Glycopeptides in clinical development: pharmacological profile and clinical perspectives. Current opinion in pharmacology, 4(5): 471–478. doi:10.1016/j.coph.2004.04.006

Higgins, D. L., Chang, R., Debabov, D. V, et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrobial agents and chemotherapy. 2005;49(3): 1127–1134. doi:10.1128/AAC.49.3.1127-1134.2005

Karlowsky, J. A., Nichol, K., & Zhanel, G. G. Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance. Clinical infectious diseases. an official publication of the Infectious Diseases Society of America;2015;61(2): S58–S68. doi:10.1093/cid/civ534

Barcia-Macay, M., Lemaire, S., Mingeot-Leclercq, M. P, et al. Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. The Journal of antimicrobial chemotherapy. 2006;58(6): 1177–1184. doi:10.1093/jac/dkl424

Leuthner, K. D., Cheung, C. M., & Rybak, M. J. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus. The Journal of antimicrobial chemotherapy. 2006;58(2): 338–343. doi:10.1093/jac/dkl235

Steed, M. E., Vidaillac, C., & Rybak, M. J. Evaluation of telavancin activity versus daptomycin and vancomycin against daptomycin-nonsusceptible Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrobial agents and chemotherapy. 2012;56(2): 955–959. doi:10.1128/AAC.05849-11

Goldstein, E. J., Citron, D. M., Merriam, C. V, et al. In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium spp. Antimicrobial agents and chemotherapy. 2004;48(6): 2149–2152. doi:10.1128/AAC.48.6.2149-2152.2004

Vibativpackageinsert. http://www.ema.europa.eu/docs/ en_GB/document_library/EPAR_-_Product_Information/ human/001240/WC500115364.pdf. (erişim tarihi: 12/12/2022)

Samara, E., Shaw, J. P., Barriere, S. L, et al. Population pharmacokinetics of telavancin in healthy subjects and patients with infections. Antimicrobial agents and chemotherapy. 2012;56(4): 2067–2073. doi:10.1128/AAC.05915-11

Stryjewski, M. E., Graham, D. R., Wilson, S. E, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clinical infectious diseases. an official publication of the Infectious Diseases Society of America;2008; 46(11): 1683–1693. doi:10.1086/587896

Stryjewski, M. E., O'Riordan, W. D., Lau, W. K., et al. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clinical infectious diseases. an official publication of the Infectious Diseases Society of America;2005; 40(11): 1601–1607. doi:10.1086/429914

Stryjewski, M. E., Chu, V. H., O'Riordan, W. D, et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrobial agents and chemotherapy. 2006;50(3): 862–867. doi:10.1128/AAC.50.3.862-867.2006

Rubinstein, E., Lalani, T., Corey, G. et al. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clinical infectious diseases. an official publication of the Infectious Diseases Society of America;2011;52(1): 31–40. doi:10.1093/cid/ciq031

Lacy, M. K., Stryjewski, M. E., Wang, W, et al. Telavancin hospital-acquired pneumonia trials: impact of Gram-negative infections and inadequate Gram-negative coverage on clinical efficacy and all-cause mortality. Clinical infectious diseases. an official publication of the Infectious Diseases Society of America;2015; 61,2: S87–S93. doi:10.1093/cid/civ536

Stryjewski, M. E., Lentnek, A., O'Riordan, et al. A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study. BMC infectious diseases. 2014;14: 289. doi:10.1186/1471-2334-14-289

Ruggero, M. A., Peaper, D. R., & Topal, J. E. Telavancin for refractory methicillin-resistant Staphylococcus aureus bacteremia and infective endocarditis. Infectious diseases (London, England). 2015;47(6): 379–384. doi:10.3109/00365548.2014.995696

Marcos LA, Camins BC. Successful treatment of vancomycin-intermediate Staphylococcus aureus pacemaker lead infective endocarditis with telavancin. Antimicrobial Agents and Chemotherapy. 2010;54(12):5376-5378.doi:10.1128/aac.00857-10.

Twilla, J. D., Gelfand, M. S., Cleveland, K. O. et al. Telavancin for the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis. The Journal of antimicrobial chemotherapy. 2011;66(11): 2675–2677. doi:10.1093/jac/dkr329

Harting, J., Fernandez, F., Kelley, R, et al. Telavancin for the treatment of methicillin-resistant Staphylococcus aureus bone and joint infections. Diagnostic microbiology and infectious disease. 2017;89(4): 294–299. doi:10.1016/j.diagmicrobio.2017.09.004

Goldstein, B. P., Draghi, D. C., Sheehan, D. J, et al. Bactericidal activity and resistance development profiling of dalbavancin. Antimicrobial agents and chemotherapy. 2007;51(4): 1150–1154. doi:10.1128/AAC.00620-06

Belley, A., Lalonde Seguin, D., Arhin, F, et al. Comparative In Vitro Activities of Oritavancin, Dalbavancin, and Vancomycin against Methicillin-Resistant Staphylococcus aureus Isolates in a Nondividing State. Antimicrobial agents and chemotherapy. 2016;60(7): 4342–4345. doi:10.1128/AAC.00169-16

Luis E. Jauregui, Simon Babazadeh, et al. Randomized, Double-Blind Comparison of Once-Weekly Dalbavancin versus Twice-Daily Linezolid Therapy for the Treatment of Complicated Skin and Skin Structure Infections, Clinical Infectious Diseases. 2005;41,(10): 1407–1415, doi:10.1086/497271

Dunne, M. W., Puttagunta, S., Giordano, P, et al. A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection. Clinical infectious diseases. an official publication of the Infectious Diseases Society of America;2016;62(5): 545–551. doi:10.1093/cid/civ982

Urania R, Sailaja P, Vadym S, et al. Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety, Open Forum Infectious Diseases. 2019;6(1): 331. doi:10.1093/ofid/ofy331

Zhanel, G. G., Schweizer, F., & Karlowsky, J. A. Oritavancin: mechanism of action. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2012;54(3): S214–S219. doi:10.1093/cid/cir920

Fetterly, G. J., Ong, C. M., Bhavnani, S. M, et al. Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose. Antimicrobial agents and chemotherapy. 2005;49(1): 148–152. doi:10.1128/AAC.49.1.148-152.2005

Belley, A., Neesham-Grenon, E., McKay, G, et al. Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro. Antimicrobial agents and chemotherapy. 2009;53(3): 918–925. doi:10.1128/AAC.00766-08

Dunbar, L. M., Milata, J., McClure, T, et al. Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial. Antimicrobial agents and chemotherapy. 2011;55(7): 3476–3484. doi:10.1128/AAC.00029-11

Bhavnani, S. M., Passarell, J. A., Owen, J, et al. Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia. Antimicrobial agents and chemotherapy. 2006;50(3): 994–1000. doi:10.1128/AAC.50.3.994-1000.2006

Corey, G. R., Kabler, H., Mehra, P, et al. Single-dose oritavancin in the treatment of acute bacterial skin infections. The New England journal of medicine. 2014;370(23): 2180–2190. doi:10.1056/NEJMoa1310422

Corey, G. R., Good, S., Jiang, H, et al. Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study. Clinical infectious disease. An official publication of the Infectious Diseases Society of America; 2015; 60(2): 254–262. doi:10.1093/cid/ciu778